ClinicalTrials.gg
CompletedNCT06117085Updated Nov 21, 2024

CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules

An interventional study of CellFX® Percutaneous Electrode (PE) System in Thyroid Nodule (Benign), sponsored by Pulse Biosciences, Inc.. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Pulse Biosciences, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2023, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Thyroid Nodule with a site in Italy — 6 open to participants now, 6 under way, none of them phase 3. Thyroid Nodule · Italy.

Started
2023
with 1 other
No phase
5 of 11
2 open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Pulse Biosciences, Inc.

Among the 11 studies in Thyroid Nodule with a site in Italy, this one is one of 2 that started in 2023, is one of 5 with no phase, and was the 7th registered.

Thyroid Nodule

208 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.

Browse Thyroid Nodule studies →

Open to participants now

6 of the 11 studies in Thyroid Nodule with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 Thyroid Nodule studies recruiting now, 33 (77%) set no upper age limit and 5 (12%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Thyroid Nodule with a site in Italy, or all of them as a file.
02

Study summary

The objective of this clinical feasibility study is to evaluate initial clinical safety and device performance of the CellFX Percutaneous Electrode (PE) System for the treatment of symptomatic benign thyroid nodules.

Read the detailed description

Cohort 1: (CellFX PE Procedure and Surgery) The first five enrolled subjects will be patients with planned thyroidectomy. The site investigator will perform the CellFX procedure followed by an ultrasound evaluation. The site investigator will then perform a partial or total thyroidectomy. Tissue samples from the CellFX targeted treated areas will be sent to the pathology lab for gross and histological evaluation. The participant will exit the study on the same day of surgery.

Cohort 2: (CellFX PE Procedure with 12 months follow-up) When Cohort 1 is completed, up to 25 subjects will undergo a CellFX treatment using a percutaneous approach under ultrasound guidance. After CellFX treatment, all subjects will be followed weekly until 1 month, 3 months, 6 months and 12 months post-CellFX PE procedure.

03

Conditions studied

  • Thyroid Nodule (Benign)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be at least 18 or no older than 80 years of age
  • Participant gives voluntary, written to participate in this clinical investigation and from whom consent has been obtained.
  • Participant must comply with study procedures including all follow-up visits diagnosis of thyroid nodule confirmed by ultrasonography ≤Grade 3 (2017 ACR TI-RADS and fine needle aspiration FNA (Bethesda category II ) with no macro-calcifications in target nodule within 30 days of enrollment
  • Participant has single nodule ≤ 6.0 cm in greatest dimension.
  • Participant may have abnormal thyroid function, such as suppressed thyrotropin (TSH) levels, at the screening visit
  • Participant has no abnormal cervical lymph nodes during screening visit examination
  • Participant has thyroid nodule causing appearance, pressure or swallowing symptoms
  • Participant has absence of abnormal vocal cord mobility by ultrasound evaluation

Exclusion criteria

Exclusion Criteria:

  • Participant has an implantable electronic medical device. (i.e., pacemaker, implantable cardioverter defibrillator)
  • Participant has an active systemic infection on the day of the CellFX PE procedure with either fever, leukocytosis or requiring intravenous antibiotics or history of head and neck, pulmonary or systemic infection in the last 2 weeks prior to CellFX PE procedure
  • Participant is known to be immune compromised
  • Participant is a member of a vulnerable population including individuals employed by the Sponsor, clinic site, or entity associated with the conduct of the study
  • Participant had previous neck irradiation
  • Participant has history of familial thyroid cancer in more than two first-degree relatives
  • Participants currently suffering from hematological diseases or bleeding tendency, or patients currently requiring continuous administration of antiplatelet and anticoagulant drugs
  • Ultrasonographic evidence of calcifications, irregular margins or sonographic features that are suspicious for
  • Nodule likely to be in contact with the recurrent laryngeal nerve on ultrasound evaluation
  • History of cardiac arrhythmia, uncontrolled hypertension, liver or kidney disease, or recent history of myocardial infarctions or structural heart disease as determined by the Investigator
  • History of a coagulation mechanism disorder or bleeding tendency
  • Abnormal contralateral vocal cord function
  • Allergy or to assigned analgesia/anesthesia
  • Females of who are nursing, pregnant, or planning to become pregnant during the study period
  • Have any condition or situation which, in the Investigator's opinion, puts the participant at significant risk, could confound the study results, or may interfere significantly with the participant's participation in the study
  • Use of any other drug, therapy, or device within 30 days prior to enrollment or concurrent participation in another research study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Percutaneous Treatment Arm

    CellFX Percutaneous Treatment under ultrasound guidance using nanosecond Pulse Field Ablation (nsPFA)

    Device: CellFX® Percutaneous Electrode (PE) System

Interventions

  • DeviceCellFX® Percutaneous Electrode (PE) System

    Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology

06

What researchers measure

Primary outcomes

  1. Number of Participants with serious adverse device effects

    The primary safety endpoint will be assessed by the incidence of serious adverse device effects

    Time frame: 1 month, 3 months, 6 months and 12 months post-CellFX PE procedure

  2. Number of Participants with Acute nodular volume loss

    Acute procedural success defined as a ≥ 50% nodule volume loss by ultrasonography and without serious adverse device effects within 6-months of the procedure

    Time frame: 6 months post-CellFX PE procedure

07

Study locations

1 site
  • Ospedale del Mare | ASLNA1 Centro
    Naples, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Nov 2024, 19 months.

Of 73 interventional studies with no phase under Thyroid Nodule, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Nov 3, 2023
StartActual
Apr 13, 2023
Primary completionActual
Nov 18, 2024
CompletionActual
Nov 18, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06117085
Lead sponsor
Pulse Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Apr 13, 2023
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Last update
Nov 21, 2024

Study contacts

Prof Stefano Spiezia, MD
principal investigator · Chief of Endocrine and Ultrasound Guided Surgery, Operative Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion